Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

MASH awareness survey completed: no treatment, just insights

NCT ID NCT07201831

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal was to gather information for future research, not to test any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,330 people

The number who actually took part.

Started

Oct 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes two population segments. The first segment is made up of Health Care Practitioners (HCPs) who self-report to being at least somewhat familiar with Metabolic dysfunction-associated steatohepatitis (MASH). The second segment consists of three subsegments defined as people who have been diagnosed with MASH, or people who have been diagnosed with Metabolic Associated Steatotic Liver Disease (MASLD), or people who have been identified as being at risk for developing MASH

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: HCP inclusion criteria * Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Licensed to practice medicine in one of the countries of interest: United States, Canada, France, Germany, Japan * Must be a practicing endocrinologist, hepatologist, cardiologist, obesity specialist, primary care physician, radiologist, nurse practitioner or physician assistant (NP/PA US only) * Must be at least "somewhat familiar" (as opposed to "not at all familiar) with Metabolic dysfunction-associated steatohepatitis (MASH) (do not need to be currently treating people with MASH) 6. Must have at least 2 years in practice 7. Must spend at least 50 percentage of their time in patient care Diagnosed patient inclusion criteria * Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Diagnosis of MASH or Metabolic Associated Steatotic Liver Disease (MASLD) within past 24 months * Live in one of the countries of interest: United States, Canada, France, Germany, Japan * Have at least one comorbid condition: obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease At risk patient inclusion criteria * Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Live in one of the countries of interest: United States, Canada, France, Germany, Japan * Must have one or more risk factors associated with MASH \[obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease\], be diagnosed with steatosis (incidental finding) or have a blood test that shows raised liver enzymes. Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction associated steatohepatitis (MASH) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novo Nordisk Investigational Site

    Plainsboro, New Jersey, 08536, United States

  • Novo Nordisk Investigational Site

    Mississauga, Canada

  • Novo Nordisk Investigational Site

    Puteaux, France

  • Novo Nordisk Investigational Site

    Mainz, Germany

  • Novo Nordisk Investigational Site

    Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.